'As Alzheimer's Drugs Hit The Market, The Race For Early Detection Blood Tests Heats Up' - Stat News
Portfolio Pulse from Happy Mohamed
The FDA has fully approved the Alzheimer's drug Leqembi, developed by Eisai and Biogen, based on its ability to slow cognitive decline. Another Alzheimer's drug, donanemab, developed by Eli Lilly, could be approved by the end of the year. The approval of these drugs has increased the need for better Alzheimer's tests, leading to a race for early detection blood tests.
July 25, 2023 | 2:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen, in partnership with Eisai, has received full FDA approval for their Alzheimer's drug Leqembi. This could potentially boost their revenues and stock price in the short term.
The full FDA approval of Leqembi is a significant milestone for Biogen and Eisai. This could lead to increased sales and revenues, which could positively impact their stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Eli Lilly's Alzheimer's drug, donanemab, could be approved by the FDA by the end of the year. If approved, this could potentially boost their revenues and stock price.
The potential FDA approval of donanemab could lead to increased sales and revenues for Eli Lilly. This could positively impact their stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80